talotrexin has been researched along with ornithine in 24 studies
| Studies (talotrexin) | Trials (talotrexin) | Recent Studies (post-2010) (talotrexin) | Studies (ornithine) | Trials (ornithine) | Recent Studies (post-2010) (ornithine) |
|---|---|---|---|---|---|
| 27 | 0 | 4 | 5,192 | 100 | 827 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (45.83) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Rosowsky, A; Wright, JE | 1 |
| Galivan, J; Rhee, MS; Rosowsky, A; Wright, JE | 1 |
| Holden, SA; Northey, D; Robinson, MF; Rosowsky, A; Teicher, BA | 1 |
| Bader, H; Keyomarsi, K; Matherly, LH; Rosowsky, A; Wright, JE | 1 |
| Galivan, J; Rhee, MS; Rosowsky, A; Sherman, ML; Tyobeka, EM | 1 |
| Bader, H; Rosowsky, A; Teicher, BA; Vaidya, CM; Wright, JE | 1 |
| Johnson, JM; Meiering, EM; Pardo, J; Rosowsky, A; Wagner, G; Wright, JE | 1 |
| Blakley, RL; Cody, V; Galitsky, N; Luft, JR; Pangborn, W; Rosowsky, A | 1 |
| Alperin, WL; Pardo, M; Rosowsky, A; Tretyakov, A; Trites, D; Wright, JE | 1 |
| Bader, H; Chen, CS; Chen, YN; Forsch, RA; Mota, CE; Pardo, J; Rosowsky, A; Vaidya, CM; Wright, JE | 1 |
| Rosowsky, A | 1 |
| Forsch, RA; Rosowsky, A; Vaidya, CM; Wright, JE | 1 |
| Bader, H; Forsch, RA; Rosowsky, A; Vaidya, CM; Wright, JE | 1 |
| Chen, Y; Rosowsky, A; Vaidya, CM; Wright, JE | 1 |
| Assaraf, YG; Bunni, MA; Drori, S; Jansen, G; Kathmann, I; Mauritz, R; Noordhuis, P; Peters, GJ; Pinedo, HM; Priest, DG; Rosowsky, A; Schornagel, JH | 1 |
| Rosowsky, A; Vaidya, CM; Wright, JE | 1 |
| Chen, YN; Rosowsky, A; Wright, JE; Yurasek, GK | 1 |
| Chattopadhyay, S; Goldman, ID; Hanscom, M; Zhao, R | 1 |
| Assaraf, YG; Ifergan, I; Jansen, G; Kaufman, Y; Rothem, L | 1 |
| Veryard, C | 1 |
| Kumar, M; Subba Rao, G; Vijayakrishnan, R | 1 |
| Adamson, PC; Norris, RE | 1 |
| Assaraf, YG; Dijkmans, BA; Gerards, AH; Jansen, G; Lems, WF; Oerlemans, R; Scheper, RJ; van der Heijden, JW | 1 |
| Frühauf, J; Gangjee, A; Hou, Z; Matherly, LH; Ning, C; O'Connor, C; Tong, N; Wallace-Povirk, A | 1 |
1 review(s) available for talotrexin and ornithine
| Article | Year |
|---|---|
PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates.
Topics: Aminopterin; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA Damage; Folic Acid Antagonists; Humans; Ornithine; Polyglutamic Acid; Pterins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Tissue Distribution | 1999 |
23 other study(ies) available for talotrexin and ornithine
| Article | Year |
|---|---|
Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Kinetics; Methotrexate; Ornithine; Pterins; Pteroylpolyglutamic Acids; Quinazolines; Tetrahydrofolate Dehydrogenase; Tritium; Tumor Cells, Cultured | 1995 |
Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Topics: Animals; Biological Transport; DNA, Neoplasm; Folic Acid; Folic Acid Antagonists; Growth Inhibitors; In Vitro Techniques; Liver Neoplasms, Experimental; Methotrexate; Ornithine; Polyglutamic Acid; Pterins; Rats; Tumor Cells, Cultured | 1994 |
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Etoposide; Folic Acid Antagonists; Head and Neck Neoplasms; Humans; Male; Methotrexate; Mice; Mice, Inbred C3H; Novobiocin; Ornithine; Pterins; Topoisomerase II Inhibitors; Trimetrexate; Tumor Cells, Cultured | 1995 |
Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin.
Topics: Aminopterin; Animals; Antineoplastic Agents; Cell Division; Folic Acid Antagonists; Humans; Methotrexate; Mice; Ornithine; Pterins; Structure-Activity Relationship; Tumor Cells, Cultured | 1994 |
Effect of a novel antifolate, N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line; Deoxyuridine; DNA, Neoplasm; Folic Acid Antagonists; Glycine; Humans; Liver Neoplasms; Ornithine; Pterins; Purines; Rats; Thymidine Monophosphate; Tumor Cells, Cultured | 1993 |
Analogues of N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Glutamates; Humans; Magnetic Resonance Spectroscopy; Methotrexate; Mice; Molecular Structure; Ornithine; Pterins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 1997 |
NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase.
Topics: Antineoplastic Agents; Binding Sites; Crystallography, X-Ray; Folic Acid Antagonists; Humans; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Methotrexate; NADP; Ornithine; Protein Conformation; Pterins; Tetrahydrofolate Dehydrogenase | 1997 |
Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes reduced with nicotinamide adenine dinucleotide phosphate and the very tight-binding inhibitor PT523.
Topics: Binding, Competitive; Crystallization; Crystallography, X-Ray; Folic Acid Antagonists; Humans; NADP; Ornithine; Protein Binding; Pterins; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 1997 |
Pharmacokinetics, antifolate activity and tissue distribution of PT523 in SCC VII tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carbon Radioisotopes; Carcinoma, Squamous Cell; Folic Acid Antagonists; Injections, Intravenous; Isotope Labeling; Male; Methotrexate; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Ornithine; Pterins; Tetrahydrofolates; Tissue Distribution | 1998 |
Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Inhibitory Concentration 50; Ornithine; Pterins; Structure-Activity Relationship; Tumor Cells, Cultured | 1998 |
The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta
Topics: 4-Aminobenzoic Acid; Aminopterin; Antineoplastic Agents; Binding Sites; Cell Division; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Folic Acid; Folic Acid Antagonists; Humans; Ornithine; Pterins; Reducing Agents; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2000 |
Analogues of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Inhibitory Concentration 50; Ornithine; Pterins; Structure-Activity Relationship; Tumor Cells, Cultured | 2000 |
Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carrier Proteins; Drug Interactions; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Leukemia; Membrane Proteins; Membrane Transport Proteins; Methotrexate; Ornithine; Pterins; Reduced Folate Carrier Protein; Tumor Cells, Cultured | 2000 |
Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Topics: Biological Transport; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Folic Acid; Folic Acid Antagonists; gamma-Glutamyl Hydrolase; Glutamates; Guanine; Homeostasis; Humans; Leukemia; Methotrexate; Ornithine; Pemetrexed; Peptide Synthases; Polyglutamic Acid; Pterins; Quinazolines; Tetrahydrofolates; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
Synthesis and in vitro antitumor activity of new deaza analogues of the nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine (PT523).
Topics: Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Ornithine; Pteridines; Pterins; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2002 |
Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity.
Topics: Amino Acids; Aminopterin; Antineoplastic Agents; Carboxylic Acids; Carrier Proteins; Humans; Membrane Transport Proteins; Ornithine; Pterins; Reduced Folate Carrier Protein; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2003 |
Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Division; Drug Resistance, Neoplasm; Folic Acid Antagonists; Glutamates; Guanine; HeLa Cells; Humans; Membrane Transport Proteins; Ornithine; Pemetrexed; Polyglutamic Acid; Pterins; Quinazolines; Reduced Folate Carrier Protein; Thiophenes | 2004 |
Coexistence of multiple mechanisms of PT523 resistance in human leukemia cells harboring 3 reduced folate carrier alleles: transcriptional silencing, inactivating mutations, and allele loss.
Topics: Alleles; Biological Transport; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia; Loss of Heterozygosity; Membrane Transport Proteins; Methotrexate; Ornithine; Pterins; Reduced Folate Carrier Protein; Response Elements; Tetrahydrofolate Dehydrogenase; Transcription Factors | 2006 |
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
Topics: Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepinones; Clinical Trials, Phase I as Topic; ErbB Receptors; Humans; Neoplasms; Ornithine; Pterins; Pyrroles; Receptor, EphA2; Societies, Scientific | 2006 |
In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery.
Topics: Amino Acid Sequence; Antitubercular Agents; Binding Sites; Computational Biology; Crystallography, X-Ray; Drug Design; Folic Acid Antagonists; Humans; Hydrogen Bonding; Ligands; Methotrexate; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Molecular Sequence Data; Mycobacterium tuberculosis; Ornithine; Peptides; Pterins; Reproducibility of Results; Substrate Specificity; Tetrahydrofolate Dehydrogenase; Triazines; Tuberculosis | 2010 |
Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Topics: Aminopterin; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Dose-Response Relationship, Drug; Folic Acid Antagonists; Glutamates; Guanine; Humans; Inhibitory Concentration 50; Jurkat Cells; Leukemia; Lymphoma; Methotrexate; Molecular Structure; Ornithine; Pemetrexed; Pterins | 2010 |
Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Folic Acid Antagonists; Humans; Male; Methotrexate; Middle Aged; Ornithine; Pterins; Quinazolines; T-Lymphocytes; Thiophenes; Trimetrexate; Tumor Necrosis Factor-alpha | 2014 |
Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
Topics: Biological Transport; Cell Proliferation; Folate Receptor 1; Folic Acid; Folic Acid Antagonists; HeLa Cells; Humans; Methotrexate; Neoplasms; Ornithine; Pemetrexed; Proton-Coupled Folate Transporter; Pterins; Reduced Folate Carrier Protein | 2021 |